๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca62 First Affiliated Hospital of Fujian Medical University45 Merck Sharp & Dohme LLC39 Fujian Medical University Union Hospital39 Fujian Cancer Hospital35
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Fuzhou

1018 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
NCT07541521Stage IIB-III NSCLC, Sleeve Lobectomy, Robotic Surgery, Neoadjuvant Chemoimmunotherapy
Shanghai Chest Hospital
Observational
100
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-04-13
Recruiting
DAREON ยฎ -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Not yet open
Prospective Lifespan Cohort of Myocardial Infarction
NCT07471763Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina
Fujian Provincial Hospital
Observational
6,000
Fuzhou
2026-04-10
Not yet open
SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis
NCT06772363Lung Cancers
Fuzhou General Hospital
Observational
200
Fuzhou
2026-04-09
By invitation
Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC
NCT07738367Non-small Cell Lung Cancer(NSCLC)
Fujian Cancer Hospital
Phase 2
20
Fuzhou
2026-04-09
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485Hepatocellular Carcinoma
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Not yet open
SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules
NCT06775587Lung Cancer in Normal and Malignant Tumors
Fuzhou General Hospital
Observational
200
Fuzhou
2026-04-08
Not yet open
SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer
NCT06775015Lung Cancer Patients
Fuzhou General Hospital
Observational
200
Fuzhou
2026-04-04
Recruiting
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Recruiting
FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis
NCT07464392Acute Pancreatitis
Changhai Hospital
Not applicable
150
Fuzhou, Quanzhou, Guangzhou, Qingyuan, Zhanjiang, Shanghai
2026-04-02
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803Plexiform Neurofibroma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
177
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang
2026-03-31
Recruiting
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
NCT07521852HCC - Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2
40
Fuzhou, Shanghai
2026-03-31
Recruiting
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
NCT07383909Aortic Dissection Type A
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
NCT07388680Radiation-induced Lung Injury, Immune-related Pneumonia
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2/3
298
Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Maoming, Shenzhen
2026-03-26
Recruiting
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
NCT07487896Advanced Esophageal Squamous Cell Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Anqing, Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2026-03-24
Not yet open
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase โ…ก Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT07465120Moderate to Severe Atopic Dermatitis
Dermavon Holdings Limited
Phase 2
160
Beijing, Fuzhou, Guangzhou, Shenzhen, Haikou, Shijiazhuang, Tangshan, Zhengzhou
2026-03-20
Recruiting
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
NCT07412691Skin Diseases
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
MK-3475AยฑCalderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
NCT07431827Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
NCT07402239Heart Failure
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Shantou, Shenzhen, Zhengzhou, Jingzhou, Wuhan
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
690
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Weihui, Zhengzhou, Wuhan
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Recruiting
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,250
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha
2026-03-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
Incyte Corporation
Phase 3
700
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-03-05
Recruiting
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
NCT07528066Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
Shanghai Chest Hospital
Observational
200
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-03-02
Recruiting
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
NCT07396480Venentoclax, Myeloid Malignancies, Conditioning, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
First Affiliated Hospital of Zhejiang University
Phase 3
186
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Hangzhou
2026-03-01
Recruiting
Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome
NCT07547098Cardiovascular Diseases (CVD), Chronic Kidney Disease, Metabolic Diseases, Cardiovascular-kidney-metabolic Syndrome
First Affiliated Hospital of Fujian Medical University
Observational
8,000
Fuzhou
2026-03-01
Not yet open
Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window
NCT07476898Stroke
First Hospital of China Medical University
Phase 3
864
Fuzhou, Anshan, Benxi, Chaoyang, Dalian, Dandong, Fushun, Fuxin
2026-03-01
Not yet open
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
800
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2026-03
Not yet open
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
NCT07483684HER2 IHC3+ Advanced Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Recruiting
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
NCT07441174Solid Tumor Cancer, PDAC
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Recruiting
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07327229Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
NCT07378527Chronic Spontaneous Urticaria (CSU)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
344
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang
2026-02-13
Recruiting
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
NCT07367516Esophageal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
105
Hefei, Beijing, Fuzhou, Lanzhou, Shantou, Nanning, Guangxi, Zunyi
2026-02-12
Not yet open
Rezvilutamide for High-Risk Prostate Cancer After Surgery
NCT07444983Prostate Cancer (Adenocarcinoma)
Fujian Medical University Union Hospital
Not applicable
33
Fuzhou
2026-02-11
Active, closed
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
NCT07493070Hepatocellular Carcinoma (HCC)
Fujian Medical University Union Hospital
Not applicable
30
Fuzhou
2026-02-10
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625Myocardial Infarction (MI)
Shanghai Zhongshan Hospital
Phase 3
512
Dalian, Shanghai, Fuzhou, Guangdong, Haโ€™erbin, Hefei, Hunan, Shenyang
2026-02-01
Recruiting
Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty
NCT07337772Adrenal Cortex Hormones, Arthroplasty, Replacement, Knee, Anesthesia, Local
First Affiliated Hospital of Fujian Medical University
Not applicable
120
Fuzhou
2026-02-01
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Nanchang, Shanghai, Chengdu, Hangzhou
2026-01-29
Recruiting
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236Cervical Cancer
Fujian Cancer Hospital
Phase 2
89
Fuzhou, Zhangzhou, Guangzhou, Nanning, Hohhot, Dalian, Jinan, Jining
2026-01-28
Recruiting
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07363642Severe Asthma
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Recruiting
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525Oral Tongue Squamous Cell Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
NCT07269145Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
86
Beijing, Fuzhou, Meizhou, Shanghai, Chengdu
2026-01-22
Recruiting
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
NCT07581834Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
Fujian Cancer Hospital
Phase 2
2,000
Fuzhou, Chengdu
2026-01-21
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562Small for Gestational Age
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Recruiting
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)
NCT07320105Non-Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 4
60
Fuzhou
2026-01-15
Recruiting
IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
NCT07376603Nasopharyngeal Cancinoma (NPC), Intensity-modulated Radiotherapy, Stage IB
Qiaojuan Guo
Observational
169
Fuzhou
2026-01-12
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
Recruiting
Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study
NCT07378358Urologic Diseases
First Affiliated Hospital of Fujian Medical University
Observational
800
Fuzhou
2026-01-01
Not yet open
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065CRT Non-Response, LBBB, HF - Heart Failure, Healthy Adult
First Hospital of China Medical University
Observational
3,240
Hefei, Wannan, Fuzhou, Guizhou, Xiamen, Lanzhou, Jiangmen, Qinhuangdao
2026-01-01
Recruiting
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT07303803MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
Shanghai Jiao Tong University School of Medicine
Phase 2
300
Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Shiyan, Changsha, Changchun
2026-01-01
Not yet open
Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
NCT07268690Nasopharyngeal Carcinoma by AJCC V9 Stage
Fujian Cancer Hospital
Phase 3
474
Fuzhou
2026-01-01
Not yet open
The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy
NCT07303231Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green
Fujian Medical University Union Hospital
Phase 3
144
Fuzhou
2026-01-01
Not yet open
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
NCT07328919Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Not yet open
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
NCT07350070HCC, Liver Cirrhosis, Portal Hypertension
Tongji Hospital
Phase 2
78
Fuzhou, Nanning, Taihe, Wuhan, Jinan, Qingdao
2025-12-31
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
NCT07419932Thyroid Cancer, Thyroid Neoplasms
Fujian Medical University
Observational
120
Fuzhou
2025-12-23
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou
2025-12-22
Not yet open
Spatiotemporal Single-cell Atlas of Peri-implant Soft Tissue Healing
NCT07279090Peri-implant Soft Tissue Healing
Stomatological Hospital Affiliated with Fujian Medical University
Not applicable
5
Fuzhou
2025-12-20
Recruiting
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
NCT07363382Prostate Cancer (Adenocarcinoma)
First Affiliated Hospital of Fujian Medical University
Phase 1/2
6
Fuzhou
2025-12-20
Recruiting
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
NCT07263308Acute Ischemic Stroke
Capital Medical University
Phase 3
1,192
Anqing, Bozhou, Fuyang, Maโ€™anshan, Suzhou, Wuhu, Beijing, Fuzhou
2025-12-18
Recruiting
A Phase II Trial of LM103 in Advanced Melanoma
NCT07310784Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
92
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun
2025-12-16
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Recruiting
Phase II Study of LM-24C5
NCT07387081Advanced Solid Tumor Cancer
LaNova Medicines Limited
Phase 2
130
Fuzhou, Shanghai
2025-12-15
Not yet open
A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure
NCT07311109Chronic Heart Failure With Reduced Ejection Fraction
Fujian Medical University
Not applicable
150
Fuzhou
2025-12-15
Recruiting
SCAN Targeted Epidural Modulation for Parkinson's Disease
NCT06919822Parkinson Disease
Changping Laboratory
Not applicable
3
Fuzhou
2025-12-08
Active, closed
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
NCT07211776Thyroid Eye Disease (TED)
Zai Lab (Shanghai) Co., Ltd.
Phase 3
108
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.
Phase 2
16
Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan
2025-12-04
Recruiting
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
A Study of LBL-024 in Combination With Paclitaxel ยฑ Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
NCT07042802Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353Primary Biliary Cholangitis
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
By invitation
Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
NCT07290764Hepatocellular Carcinoma
Fujian Provincial Hospital
Observational
729
Fuzhou
2025-12-01
Recruiting
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity
NCT07587944AML, Adult
Fujian Medical University Union Hospital
Observational
405
Fuzhou
2025-12-01
Not yet open
A Phase โ… /โ…กa Study of SNUG01 in Adult Subjects With ALS
NCT07169175Amyotrophic Lateral Sclerosis (ALS)
SineuGene Therapeutics Co., Ltd.
Phase 1/2
21
Beijing, Fuzhou, Hangzhou
2025-12-01
Recruiting
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
NCT07246564Myasthenia Gravis
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
Recruiting
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
NCT06787183Locally Advanced Rectal Cancer With Liver Metastases
Fujian Cancer Hospital
Phase 2
42
Fuzhou
2025-12-01
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOYยฎ (US-Sourced YERVOYยฎ) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 1/2
152
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang
2025-11-24
Recruiting
FMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder
NCT07532395Autism Spectrum Disorder
Peking University
Not applicable
184
Fuzhou
2025-11-22
Recruiting
AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomized Cohort Study
NCT07251114Esophageal Cancer Stage, Early Esophageal Cancer
Fujian Provincial Hospital
Not applicable
200
Fuzhou, Putian
2025-11-20
Recruiting
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
NCT07328854Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Haikou, Shijiazhuang, Harbin
2025-11-18
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Rows per page Showing 101–200 of 1018
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

594 of the 1,018 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 114 have not yet opened recruitment, 287 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.